AU2004258821A1 - Antibacterial methods and compositions - Google Patents

Antibacterial methods and compositions Download PDF

Info

Publication number
AU2004258821A1
AU2004258821A1 AU2004258821A AU2004258821A AU2004258821A1 AU 2004258821 A1 AU2004258821 A1 AU 2004258821A1 AU 2004258821 A AU2004258821 A AU 2004258821A AU 2004258821 A AU2004258821 A AU 2004258821A AU 2004258821 A1 AU2004258821 A1 AU 2004258821A1
Authority
AU
Australia
Prior art keywords
aureus
mupirocin
composition
mrsi
trna synthetase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004258821A
Other languages
English (en)
Inventor
Ian A. Critchley
Joseph Guiles
Nebojsa Janjic
Theodore M. Tarasow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiovascular Systems Inc
Original Assignee
Replidyne Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replidyne Inc filed Critical Replidyne Inc
Publication of AU2004258821A1 publication Critical patent/AU2004258821A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2004258821A 2003-05-01 2004-05-03 Antibacterial methods and compositions Abandoned AU2004258821A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46737703P 2003-05-01 2003-05-01
US60/467,377 2003-05-01
US48648203P 2003-07-10 2003-07-10
US60/486,482 2003-07-10
PCT/US2004/013614 WO2005009336A2 (en) 2003-05-01 2004-05-03 Antibacterial methods and compositions

Publications (1)

Publication Number Publication Date
AU2004258821A1 true AU2004258821A1 (en) 2005-02-03

Family

ID=34107519

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004258821A Abandoned AU2004258821A1 (en) 2003-05-01 2004-05-03 Antibacterial methods and compositions

Country Status (6)

Country Link
US (1) US20040224981A1 (https=)
EP (1) EP1619947A4 (https=)
JP (1) JP2007502861A (https=)
AU (1) AU2004258821A1 (https=)
CA (1) CA2523651A1 (https=)
WO (1) WO2005009336A2 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004218481A1 (en) * 2003-03-03 2004-09-16 Replidyne Inc Substituted thiophenes with antibacterial activity
CA2602411C (en) 2005-03-23 2015-02-24 Oculus Innovative Sciences, Inc. Method of treating second and third degree burns using oxidative reductive potential water solution
DK1879877T3 (da) 2005-05-03 2013-04-15 Ranbaxy Lab Ltd Antimikrobielle midler
CA2637178C (en) 2006-01-20 2018-09-04 Oculus Innovative Sciences, Inc. Methods of preventing or treating sinusitis with oxidative reductive potential water solution
ES2429289T3 (es) * 2006-09-26 2013-11-14 Crestone, Inc. Compuestos enantioméricos con actividad antibacteriana
ES2392897T3 (es) * 2006-09-26 2012-12-14 Crestone, Inc. Compuestos tienopiridona sustituidos con actividad antibacteriana
WO2010099477A2 (en) 2009-02-27 2010-09-02 Atyr Pharma, Inc. Polypeptide structural motifs associated with cell signaling activity
WO2010148004A1 (en) 2009-06-15 2010-12-23 Oculus Innovative Sciences, Inc. Solution containing hypochlorous acid and methods of using same
US8980253B2 (en) 2010-04-26 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
EP2563382B1 (en) 2010-04-27 2017-06-07 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
CN103140233B (zh) 2010-05-03 2017-04-05 Atyr 医药公司 与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
CN103096912A (zh) * 2010-05-03 2013-05-08 Atyr医药公司 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2797799C (en) 2010-05-03 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases
US9062301B2 (en) 2010-05-04 2015-06-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases
JP6008844B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CN103096914B (zh) 2010-05-17 2015-08-12 Atyr医药公司 与亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2800375C (en) 2010-05-27 2021-03-09 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
EP2575857B1 (en) 2010-06-01 2018-01-24 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
US20130202576A1 (en) 2010-07-12 2013-08-08 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
WO2012009289A2 (en) 2010-07-12 2012-01-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
EP2593125B1 (en) 2010-07-12 2017-11-01 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
WO2012014109A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
CA2812795C (en) 2010-10-06 2021-08-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl trna synthetases
US20130245060A1 (en) * 2010-10-08 2013-09-19 Helperby Therapeutics Limited Novel composition
WO2012054738A1 (en) * 2010-10-22 2012-04-26 Brown University Combination of an aminoacyl - trna synthetase inhibitor with a further antibacterial agent for attenuating multiple drug resistance
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
US9816084B2 (en) 2011-12-06 2017-11-14 Atyr Pharma, Inc. Aspartyl-tRNA synthetases
US9822353B2 (en) 2011-12-06 2017-11-21 Atyr Pharma, Inc. PEGylated aspartyl-tRNA synthetase polypeptides
WO2013115926A2 (en) 2011-12-29 2013-08-08 Atyr Pharma, Inc. Aspartyl-trna synthetase-fc conjugates
IN2014DN09302A (https=) * 2012-04-13 2015-07-10 Becton Dickinson Co
CN105378075B (zh) 2013-03-15 2022-04-05 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
WO2016029146A1 (en) 2014-08-22 2016-02-25 University Of Washington Specific inhibitors of methionyl-trna synthetase
JP2019196307A (ja) * 2016-09-15 2019-11-14 武田薬品工業株式会社 複素環アミド化合物
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
US11261201B2 (en) 2018-01-12 2022-03-01 President And Fellows Of Harvard College TRNA synthetase inhibitors
EP4190780A4 (en) * 2020-08-25 2024-03-20 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. MUPIROCIN EXTRACTION PROCESS

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1196284A (en) * 1982-05-28 1985-11-05 Joshua Oduro-Yeboah Pharmaceutical formulations
GB8415579D0 (en) * 1984-06-19 1984-07-25 Beecham Group Plc Compounds
IE59628B1 (en) * 1986-06-26 1994-03-09 Beecham Group Plc Treatment of fungal infections
KR100374462B1 (ko) * 1993-10-22 2003-06-09 스미스클라인 비참 코포레이션 신규조성물
GB9424562D0 (en) * 1994-12-06 1995-01-25 Giltech Ltd Product
GB9507825D0 (en) * 1995-04-18 1995-05-31 Wet Pieter M De Method of treatment
US5726195A (en) * 1995-07-28 1998-03-10 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
US6169102B1 (en) * 1996-06-25 2001-01-02 Takeda Chemical Industries, Ltd. Oxazolone derivatives and their use as anti-Helicobacter pylori agent
US6448059B1 (en) * 1996-09-13 2002-09-10 Thomas Jefferson University Methods and composition for inhibition of tRNA activities
US5824657A (en) * 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
US5939458A (en) * 1997-09-22 1999-08-17 Henry; James P. Reduction of hair growth
PL343680A1 (en) * 1998-04-29 2001-08-27 Smithkline Beecham Plc Quinolones used as mrs inhibitors and bactericides
WO2000017206A1 (en) * 1998-09-18 2000-03-30 Cubist Pharmaceuticals, Inc. Tetracyclic heterocycles as antimicrobial agents
GB9822241D0 (en) * 1998-10-12 1998-12-09 Smithkline Beecham Plc Novel compounds
US6333344B1 (en) * 1999-05-05 2001-12-25 Merck & Co. Prolines as antimicrobial agents
ES2226839T3 (es) * 1999-05-05 2005-04-01 MERCK & CO., INC. Nuevos catecoles como agentes antimicrobianos.
WO2000071524A1 (en) * 1999-05-19 2000-11-30 Smithkline Beecham Plc 2-nh-pyridones and pyrimidones as mrs inhibitors
GB9911594D0 (en) * 1999-05-19 1999-07-21 Smithkline Beecham Plc Novel compounds
IL137363A (en) * 2000-07-18 2005-12-18 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
GB0228545D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Novel compounds
GB0302546D0 (en) * 2003-02-04 2003-03-12 Glaxo Group Ltd Novel compounds
AU2004218481A1 (en) * 2003-03-03 2004-09-16 Replidyne Inc Substituted thiophenes with antibacterial activity
DE10318991A1 (de) * 2003-04-25 2004-11-18 Heraeus Kulzer Gmbh & Co. Kg Poröser Körper mit antibiotischer Beschichtung, Verfahren zur Herstellung sowie Verwendung

Also Published As

Publication number Publication date
CA2523651A1 (en) 2005-02-03
EP1619947A4 (en) 2006-05-31
WO2005009336A2 (en) 2005-02-03
WO2005009336A9 (en) 2005-04-14
JP2007502861A (ja) 2007-02-15
EP1619947A2 (en) 2006-02-01
WO2005009336A3 (en) 2005-10-13
US20040224981A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
AU2004258821A1 (en) Antibacterial methods and compositions
RU2609259C2 (ru) Пиримидиновые ингибиторы гиразы и топоизомеразы iv
UA124661C2 (uk) Композиція, що містить антибіотик та диспергатор або антиадгезивний агент
CN103781787A (zh) 含氮化合物及其用途
US12150937B2 (en) NLRP3 modulators
KR20080038380A (ko) 항균제로서의 퀴놀린 유도체
RU2527769C2 (ru) Производные 5-гидроксиметилоксазолидин-2-она для лечения бактериальных кишечных заболеваний
US12187706B2 (en) NLRP3 modulators
KR20150089086A (ko) 박테리아 감염을 치료하기 위한 조성물 및 방법
JP6411482B2 (ja) 窒素含有化合物およびその使用
US9814719B2 (en) Methods and compositions for treating bacterial infection
AU2019349438B2 (en) Indane derivatives for use in the treatment of bacterial infection
US12016874B2 (en) Methods and compositions for treating carbapenem-resistant klebsiella pneumoniae infections
KR101850265B1 (ko) 항균제 및 타조박탐을 포함하는 조성물
EP1618106B1 (en) Carbacephem beta-lactam antibiotics
KR101329587B1 (ko) 항균제로서의 퀴놀린 유도체
AU2003303953B2 (en) Antibacterial pyrazole carboxylic acid hydrazides
US20210094954A1 (en) Preparation methods and applications of 3,5-disubstituted methylpyrazolo[1,5-a]pyrimidine-7-hydroxylic salts
KR20080021156A (ko) 항균제로서 퀴놀린 유도체
EP2285802B1 (en) Oxo-imidazolyl compounds having antibacterial activity
CN120665042A (zh) 活性氧激活型抗菌前药及其在治疗细菌感染中的应用
US20250161266A1 (en) Antibacterial 4.5 Diaryl-Thiophen-2-YL Hexafluoropropan-2-OLS
CN120424016A (zh) 一种多卤代喹唑啉酮生物碱及其在抗金黄色葡萄球菌中的应用
KR101318181B1 (ko) 항균제로서의 퀴놀린 유도체
CA3158337A1 (en) Nitrogen containing bicyclic compounds

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application